Roche enters $200m hep B treatment collaboration

31-10-2019

Saman Javed

Roche enters $200m hep B treatment collaboration

Testing / Shutterstock.com

Roche has entered into a $200 million agreement to licence Dicerna’s GalXC RNAi platform technology to develop novel therapies for the treatment of chronic hepatitis B.


Dicerna, hepatitis B, Roche, licencing agreement, patents, viral genes, novel therapies, big pharma

LSIPR